TB CAB
By
TB CAB
Published: Feb. 9, 2021, 8:17 p.m.·
Tags:
TB CAB
Deadline for applications: 19 February 2021
Read More →
By
TB CAB
Published: July 14, 2020, 8:59 p.m.·
Tags:
Drug-resistant TB,
Treatment,
Access,
Advocacy
TB CAB Access Considerations Statement Regarding Johnson & Johnson Announcement of Bedaquiline Price Reduction
Read More →
By
Médecins Sans Frontières,
Treatment Action Group,
DR-TB STAT,
TB CAB,
Partners In Health
Published: June 7, 2019, 11:44 a.m.·
Tags:
Drug-resistant TB,
Guidelines,
Advocacy
Advocates request an urgent in-person meeting with the WHO leadership to discuss concrete actions to address technical and guideline development process-related issues previously raised.
Read More →
By
TB CAB
Published: May 18, 2019, 1:58 p.m.·
Tags:
Medicines,
Advocacy
TB CAB releases document outlining key considerations regarding pretomanid in anticipation of FDA public advisory committee meeting on the TB Alliance's new drug application for pretomanid.
Read More →
By
Partners In Health,
Médecins Sans Frontières,
Treatment Action Group,
DR-TB STAT,
TB CAB
Published: May 18, 2019, 1:38 p.m.·
Tags:
Drug-resistant TB,
Guidelines,
Advocacy
Advocates call on WHO leadership to act immediately and correct specific technical errors in the WHO guidelines for the treatment of drug-resistant TB.
Read More →
By
TB CAB,
Treatment Action Group
Published: April 4, 2019, 3:21 p.m.·
Tags:
Vaccines,
Scientific research,
Research and development,
Advocacy
Statement by the Global TB Community Advisory Board to the High-level consultation on accelerating the development of the M72/AS01E tuberculosis vaccine candidate
Read More →
By
TB CAB
Published: March 12, 2019, 8:16 p.m.·
Tags:
Drug-resistant TB,
Treatment,
Access,
Advocacy
Global TB CAB welcomes confirmation of safety of using bedaquiline and delamanid together, urges uptake.
Read More →
By
TB CAB
Published: Oct. 17, 2018, 10:03 p.m.·
Tags:
Drug-resistant TB,
Treatment,
Access,
Advocacy
Advocates ask Otsuka to lower the price of delamanid in line with Médecins sans Frontières target regimen cost of $500.
Read More →
By
Treatment Action Group,
TB CAB,
DR-TB STAT,
TB Proof
Published: Aug. 29, 2018, 5:05 p.m.·
Tags:
Drug-resistant TB
Treatment Action Group (TAG), the Global TB Community Advisory Board (TB CAB), the Drug-Resistant TB Treatment Scale-up Action Team (DR-TB STAT) and TB Proof hosted a webinar on 16 August 2018 on implementing an injectable-free regimen for drug-resistant TB.
Read More →
By
TB CAB,
Treatment Action Group
Published: Aug. 28, 2018, 2:31 p.m.·
Tags:
Drug-resistant TB,
Treatment,
Guidelines,
Advocacy
The WHO, Ministries of Health and Finance, donors, implementers, technical assistance providers, civil society, and communities must work together to ensure rapid implementation.
Read More →
Page 1 of 6 · Total posts: 10
1
2
Last→